Cargando…
Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience
Introduction: The hallmark of chronic myeloid leukemia (CML) is the development of the fusion gene, BCR-ABL which has unopposed tyrosine kinase activity. The first tyrosine kinase inhibitor (TKI) imatinib is claimed to have superior efficacy and side effect profile as compared to traditional treatme...
Autores principales: | Saleem, Umera, Hafeez, Talha, Raza, Syed Ali, Tahir, Muhammad, Khalid, Fatima, Islam, Muhammad Khurrum |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249755/ https://www.ncbi.nlm.nih.gov/pubmed/32467801 http://dx.doi.org/10.7759/cureus.7826 |
Ejemplares similares
-
Risk Stratification of Chronic Myeloid Leukemia According to Different Prognostic Scores
por: Aijaz, Javeria, et al.
Publicado: (2020) -
The Frequency of Aberrant CD7 Antigen Expression in Acute Myeloid Leukaemia Patients
por: Raza, Hassan, et al.
Publicado: (2022) -
Tryptase Positivity in Chronic Myeloid Leukemia With Marked Basophilia
por: Khafateh, Youssef, et al.
Publicado: (2020) -
Acute Myeloid Leukemia Presenting As Thrombotic Thrombocytopenic Purpura
por: Kucharik, Michael P, et al.
Publicado: (2020) -
Antimicrobial Resistance Patterns: Review of the Antibiogram of a Surgical Unit in a Public Tertiary Care Hospital of Pakistan
por: Kathia, Usama Muhammad, et al.
Publicado: (2020)